Article 2026 · 0 atıf

Cancer prevalence and prognosis among individuals living with HIV and AIDS in Turkey: Multicenter BUHASDER study

Guler, Ozlem, Akhan, Sila, Cagatay, Atahan, Batirel, Ayse, Sargin Altunok, Elif, Bolukcu, Sibel, Ozkan Ozdemir, Hulya, Duman, Emine Ilay, Toygar Deniz, Muge, Ozyigitoglu, Derya, Ozden, Kemalettin, Alay, Handan, Seyman, Derya, Turken, Melda, Calik, Sebnem, Caydasi, Ozge, Ozturk Engin, Derya, Gunal, Ozgur, Topal, Seyma, Karabay, Oguz, Sarigul, Figen, Karakoc Parlayan, Hanife Nur, Kilinc Toker, Aysin, Aydin, Ozlem, Bayhan, Emre, Ergen, Pinar, Ince, Nevin, Kaya, Safak, Arslan Ozel, Selcan, Ozsahin, Aybegum, Gurbuz, Esra, Sahin, Ahmet, Balci, Sibel, Kose, Sukran

Özet

Background This multicentre study evaluated the prevalence, distribution, and risk factors of cancer among people living with HIV (PLWH) in Turkey over two decades. Mortality rates and factors were also investigated.Methods This retrospective cohort study included 154 adults diagnosed with cancer and HIV between 2008 and 2024. Data were collected from the medical records. The demographics, clinical characteristics, cancer types, treatments, and outcomes were evaluated. The risk factors for ADCs and mortality were defined using multivariate logistic regression and Cox regression. The estimated survival time was determined using Kaplan-Meier analysis.Results Among 8708 PLWH, cancer prevalence was 1.8% (95% CI:1.5-2). ADCs (66.9%) were twice as frequent as NADCs (33.1%). Most prevalent cancers were non-Hodgkin lymphoma (35.1%), Kaposi sarcoma (29.9%), and lung cancer (7.8%). Age <= 54 years, CD4 + T lymphocyte count <= 94/mm3, and HHV-8 co-infection were risk factors for ADCs. Mortality rate was 32%. Non-Hodgkin lymphoma and CD4 + T lymphocyte count <= 232/mm3 at treatment completion predicted mortality. The 3-years overall survival rate was 67.6%.Conclusions This study offers insights into cancer burden among PLWH in Turkey. High rates of ADCs and mortality highlight the importance of early HIV diagnosis and antiretroviral therapy access to reduce cancer burden in this population.

Anahtar Kelimeler

HIV acquired immunodeficiency syndrome malignancy cancer mortality POPULATION

WoS Kategorileri

Immunology Infectious Diseases

Sürdürülebilir Kalkınma Amaçları

Sağlık ve Kaliteli Yaşam

Künye

Dergi: INTERNATIONAL JOURNAL OF STD & AIDS
Yıl: 2026
Cilt: 37
Sayı: 5
Sayfa: 500-510
ISSN: 0956-4624
eISSN: 1758-1052
DOI: 10.1177/09564624251405965
WoS UID: WOS:001631479200001

Yayını aç (DOI)